TRVI

Trevi Therapeutics, Inc. Common Stock US Stock
$2.16
Open: $2.23 High: $2.24 Low: $2.01 Close: $2.01
Range: 2022-06-27 - 2022-06-28
Volume:124,017
Market: Extended-hours
TRVI
Trevi Therapeutics, Inc. Common Stock 195 CHURCH STREET https://www.trevitherapeutics.com
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
  • CEO:
  • Employees: 23
  • Sector:
  • Industry:
Latest Stocks Posts
Card image
Card image
Card image
TRVI News
Latest news about the TRVI